Rimonabant + Placebo (for Rimonabant)

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Carotid Artery Plaque

Conditions

Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X

Trial Timeline

Aug 1, 2005 → Apr 1, 2009

NCT ID

NCT00228176

About Rimonabant + Placebo (for Rimonabant)

Rimonabant + Placebo (for Rimonabant) is a phase 3 stage product being developed by Sanofi for Carotid Artery Plaque. The current trial status is terminated. This product is registered under clinical trial identifier NCT00228176. Target conditions include Carotid Artery Plaque, Arteriosclerosis, Obesity.

What happened to similar drugs?

3 of 5 similar drugs in Carotid Artery Plaque were approved

Approved (3) Terminated (0) Active (2)

✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved

✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved

✅EvolocumabAmgenApproved

🔄RosuvastatinAstraZenecaPhase 3

🔄Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00577148	Phase 3	Terminated	Feb 1, 2008	Feb 1, 2009	Fatty Liver
NCT00576667	Phase 3	Terminated	Jan 1, 2008	Feb 1, 2009	Fatty Liver
NCT00478972	Phase 3	Terminated	Apr 1, 2007	Jan 1, 2009	Obesity
NCT00325650	Phase 3	Terminated	May 1, 2006	Mar 1, 2009	Prediabetic State
NCT00299325	Phase 3	Completed	Feb 1, 2006	Jul 1, 2008	Metabolic Syndrome
NCT00263042	Phase 3	Terminated	Dec 1, 2005	Apr 1, 2009	Cardiovascular Disease
NCT00228176	Phase 3	Terminated	Aug 1, 2005	Apr 1, 2009	Carotid Artery Plaque

Competing Products

9 competing products in Carotid Artery Plaque

See all competitors

Product	Company	Stage	Hype Score
Abciximab	Eli Lilly	Phase 1/2	24
Rosuvastatin	AstraZeneca	Phase 3	40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	39
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	43
simvastatin + placebo	Merck	Pre-clinical	26
Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin	Merck	Phase 2	35
Evolocumab	Amgen	Approved	39
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Gadobutrol (Gadovist, BAY86-4875)	Bayer	Phase 3	37